Nichola’s story
I am 48 years old, live in England and am married with 2 daughters, aged 14 and 17. I am an assistant head in a primary school.
Anna’s story
My name is Anna and I live in Spain. My journey with FL started in October 2018 when I was 34. When the year started, I only had a strong wish for that year: to start a family.
Steve’s story
My name is Steve and I live in Australia. I recently retired after 40 years in the IT industry (and by recently I mean it sort of all was decided upon last Monday) I am divorced with three adult children.
Simon’s story
My name is Simon. I am 71 yrs old, married to my all suffering wonderful wife Linda for 45 years.
FLF hosts first International Summit in Tel Aviv
The Follicular Lymphoma Foundation (FLF) proudly hosted its first international FL Summit, titled “Joining Forces to Cure Follicular Lymphoma,” in Tel Aviv, Israel. The summit, held in January 2023, exceeded all expectations and marked a major milestone for the FLF. The summit brought together a diverse group of lymphoma experts, scientists, researchers, and representatives from […]
ASH Annual Meeting 2022 – Research and insight summary
ASH Annual Meeting 2022 – summary and key take-outs By Dr Zoe Drymoussi During the 9-12th December 2022, the FLF team attended, in person, for the biggest events of the year in the world of haematology – the American Society of Hematology (ASH) annual meeting. More than 25,000 delegates, showcasing 3000+ abstracts, took over the […]
Looking back over the last 25 years for FL – the Rituximab era
Looking back over the last 25 years for FL – the Rituximab era By Dr Mitchell Smith, Chief Medical Officer A recent re-publication marking 25 years since the seminal 1998 Journal of Clinical Oncology paper (1) upon which Rituximab was approved for relapsed/refractory follicular or low-grade lymphoma (1997 by U.S. FDA, and 1998 by European […]
Educational workshop covering targeted therapies for FL
Educational workshop covering targeted therapies for FL With the ever-evolving landscape of targeted and cellular therapies, how can the most recent advances be incorporated into follicular lymphoma patient care? Which diagnostic and prognostic features are important for decision-making? How do we optimise treatment options in the 1st, 2nd and 3rd line setting? These questions and […]
The FLF’s Precision Medicine Programme research goals
The FLF’s Precision Medicine Programme Research Goals Technical abstract: The FLF undertook extensive landscaping and scoping work, identifying a substantial set of unmet needs in follicular lymphoma that the Precision Medicine Programme (PMP) could help to address. This could significantly push the field forward for FL. Several unmet needs remain unresolved: Improve understanding of the […]
Research in focus: Bi-specific antibodies approval.
Research in focus: Bi-specific antibodies approval. By Dr. Zoe Drymoussi Over the last few years, a promising new class of treatments for advanced-stage FL has been in development, with mosunetuzumab being the first in this class to be approved in Europe (by the EMA; European Medicines Agency) and likely to receive U.S. FDA (Federal Drug […]